Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0XFQVE
ADC Name	SYSA-1801
Synonyms	EO 3021; EO-3021; EO3021; SYSA1801 Click to Show/Hide
Organization	CSPC Pharmaceutical Group Ltd.; Elevation Oncology, Inc.
Drug Status	Phase 1
Indication	In total 3 Indication(s) Gastric cancer [ICD11:2B72] Phase 1 Lung cancer [ICD11:2C25] Phase 1 Pancreatic cancer [ICD11:2C10] Phase 1
Drug-to-Antibody Ratio	2
Structure
	3D MOL	2D MOL
Antibody Name	Anti-CLDN18.2 mAb SYSA-1801		Antibody Info
Antigen Name	Claudin-18.2 (CLDN18.2)		Antigen Info
Payload Name	Monomethyl auristatin E		Payload Info
Therapeutic Target	Microtubule (MT)		Target Info
Linker Name	PEG3-Val-Cit-PABC		Linker Info

General Information of The Activity Data Related to This ADC

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Standard Type	NCT Number	Clinical Status	Clinical Trial Description
Objective Response Rate (ORR)	NCT05009966	Phase 1	A phase 1 trial to evaluate safety, tolerability, pharmacokinetics, immunogenicity and initial efficacy of SYSA1801 in the treatment of CLDN 18.2 positive advanced malignant solid tumor.

Full List of Activity Data of This Antibody-drug Conjugate

Identified from the Human Clinical Data

Click To Hide/Show 1 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC				[1]
Efficacy Data	Objective Response Rate (ORR)	47.10% (gastric cancer) 33.30% (1.00 mg/kg) 40.00% (2.00 mg/kg) 100.00% (2.50 mg/kg) 20.00% (3.00 mg/kg) 38.10% (all)
Patients Enrolled	Patients with resistant/refractory solid tumors that express CLDN18.2 who progressed on or were intolerant to standard treatment, or had no standard treatment were recruited.. ECOG score of 0-2.
Administration Dosage	0.50 up to 3.00 mg/kg on day 1, administered once every 3 weeks.
*Related Clinical Trial*
NCT Number	NCT05009966	Clinical Status	Phase 1
Clinical Description	A phase 1 trial to evaluate safety, tolerability, pharmacokinetics, immunogenicity and initial efficacy of SYSA1801 in the treatment of CLDN 18.2 positive advanced malignant solid tumor.

References

Ref 1	Phase I, first-in-human study of AbGn-107, a novel antibody-drug conjugate (ADC), in patients with gastric, colorectal, pancreatic or biliary cancers. J Clin Oncol. 2020 38:15_suppl, e16771-e16771.